{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:23:07Z","timestamp":1790796187915,"version":"4.1.0"},"reference-count":148,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.autrev.2022.103085","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T22:36:43Z","timestamp":1648161403000},"page":"103085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases"],"prefix":"10.1016","volume":"21","author":[{"given":"Smadar","family":"Gertel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Polachek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Elkayam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Furer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2022.103085_bb0005","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaut.2009.09.008","article-title":"Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases","volume":"33","author":"Cooper","year":"2009","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103085_bb0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJM200108023450506","article-title":"Autoimmune diseases","volume":"345","author":"Davidson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103085_bb0015","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins","volume":"136","author":"Mosmann","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0020","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood-2012-09-378653","article-title":"Essentials of Th17 cell commitment and plasticity","volume":"121","author":"Muranski","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103085_bb0025","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","article-title":"Follicular helper CD4 T cells (TFH)","volume":"29","author":"Crotty","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0030","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.immuni.2009.03.003","article-title":"Follicular helper T cells: lineage and location","volume":"30","author":"Fazilleau","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2022.103085_bb0035","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nri3464","article-title":"The plasticity and stability of regulatory T cells","volume":"13","author":"Sakaguchi","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2022.103085_bb0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1034\/j.1600-065X.2001.1820102.x","article-title":"Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance","volume":"182","author":"Sakaguchi","year":"2001","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2022.103085_bb0050","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri2138","article-title":"Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans","volume":"7","author":"Roncarolo","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0055","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0060","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.4049\/jimmunol.167.3.1245","article-title":"CD4+CD25high regulatory cells in human peripheral blood","volume":"167","author":"Baecher-Allan","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0065","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/39614","article-title":"A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis","volume":"389","author":"Groux","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2022.103085_bb0070","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature09370","article-title":"Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance","volume":"467","author":"Kim","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2022.103085_bb0075","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.4049\/jimmunol.175.7.4180","article-title":"Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells","volume":"175","author":"Lim","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0080","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nm.2425","article-title":"Foxp3+ follicular regulatory T cells control the germinal center response","volume":"17","author":"Linterman","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2022.103085_bb0085","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0090","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1172\/JCI118779","article-title":"Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients","volume":"98","author":"Fukaura","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2022.103085_bb0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri1032","article-title":"Natural versus adaptive regulatory T cells","volume":"3","author":"Bluestone","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1084\/jem.20020590","article-title":"CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness","volume":"196","author":"Piccirillo","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2022.103085_bb0105","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/icb.2010.137","article-title":"Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns","volume":"89","author":"Miyara","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.autrev.2022.103085_bb0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/intimm\/dxm014","article-title":"Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production","volume":"19","author":"Allan","year":"2007","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/eji.200636435","article-title":"Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells","volume":"37","author":"Wang","year":"2007","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0120","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20060772","article-title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","volume":"203","author":"Liu","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2022.103085_bb0125","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2022.103085_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaut.2013.12.015","article-title":"Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: roles of IL-17 and TNF-alpha","volume":"52","author":"Gradolatto","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103085_bb0135","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1365-2249.2008.03686.x","article-title":"Reduction of forkhead box P3 levels in CD4+CD25high T cells in patients with new-onset systemic lupus erythematosus","volume":"153","author":"Zhang","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0140","doi-asserted-by":"crossref","first-page":"19396","DOI":"10.1073\/pnas.0806855105","article-title":"Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis","volume":"105","author":"Flores-Borja","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2022.103085_bb0145","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1002\/art.20499","article-title":"CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid","volume":"50","author":"van Amelsfort","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103085_bb0150","first-page":"5366","article-title":"Decreased regulatory T-cell frequency and interleukin-35 levels in patients with rheumatoid arthritis","volume":"16","author":"Zhang","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.autrev.2022.103085_bb0155","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cellimm.2008.05.007","article-title":"CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis","volume":"253","author":"Han","year":"2008","journal-title":"Cell Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0160","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/immu.200390024","article-title":"Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis","volume":"33","author":"Cao","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0165","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-3083.2005.01656.x","article-title":"The presence of cytokine-suppressive CD4+CD25+ T cells in the peripheral blood and synovial fluid of patients with rheumatoid arthritis","volume":"62","author":"Liu","year":"2005","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0170","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2249.2005.02754.x","article-title":"CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis","volume":"140","author":"Mottonen","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0175","doi-asserted-by":"crossref","first-page":"R335","DOI":"10.1186\/ar1192","article-title":"CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease","volume":"6","author":"Cao","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2022.103085_bb0180","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.3899\/jrheum.110283","article-title":"CD4+CD25(high)CD127(low\/\u2212) Treg cell frequency from peripheral blood correlates with disease activity in patients with rheumatoid arthritis","volume":"38","author":"Kawashiri","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2022.103085_bb0185","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00296-011-1984-x","article-title":"Disturbed Th17\/Treg balance in patients with rheumatoid arthritis","volume":"32","author":"Niu","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2022.103085_bb0190","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00241263","article-title":"Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand","volume":"39","author":"Huard","year":"1994","journal-title":"Immunogenetics"},{"key":"10.1016\/j.autrev.2022.103085_bb0195","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2022.103085_bb0200","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/eji.200526090","article-title":"Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells","volume":"35","author":"Kisielow","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0205","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4049\/jimmunol.0800185","article-title":"LAG-3 regulates plasmacytoid dendritic cell homeostasis","volume":"182","author":"Workman","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0210","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.4049\/jimmunol.169.10.5392","article-title":"Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3","volume":"169","author":"Workman","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0215","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/14712598.2011.540563","article-title":"The CD4-like molecule LAG-3, biology and therapeutic applications","volume":"15","author":"Sierro","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.autrev.2022.103085_bb0220","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1073\/pnas.94.11.5744","article-title":"Characterization of the major histocompatibility complex class II binding site on LAG-3 protein","volume":"94","author":"Huard","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2022.103085_bb0225","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.4049\/jimmunol.161.8.4058","article-title":"CD3\/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3\/TCR signaling","volume":"161","author":"Hannier","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0230","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/eji.1830260533","article-title":"T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding","volume":"26","author":"Huard","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0235","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/eji.1830250949","article-title":"CD4\/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins","volume":"25","author":"Huard","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0240","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1002\/eji.1830241246","article-title":"Lymphocyte-activation gene 3\/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes","volume":"24","author":"Huard","year":"1994","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0245","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2022.103085_bb0250","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.4049\/jimmunol.0903879","article-title":"LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites","volume":"184","author":"Camisaschi","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0255","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.4049\/jimmunol.1002050","article-title":"MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis","volume":"186","author":"Hemon","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0260","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/ecco-jcc\/jjaa054","article-title":"Lymphocyte activation gene (LAG)-3 is associated with mucosal inflammation and disease activity in ulcerative colitis","volume":"14","author":"Slevin","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2022.103085_bb0265","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/eji.200939874","article-title":"Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4","volume":"40","author":"Woo","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0270","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.emboj.7601520","article-title":"Metalloproteases regulate T-cell proliferation and effector function via LAG-3","volume":"26","author":"Li","year":"2007","journal-title":"EMBO J"},{"key":"10.1016\/j.autrev.2022.103085_bb0275","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/cei.13646","article-title":"CD4(+) LAG-3(+) T cells are decreased in active psoriatic arthritis patients and their restoration in vitro is mediated by TNF inhibitors","volume":"206","author":"Gertel","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0280","first-page":"269","article-title":"LAG-3 in cancer immunotherapy","volume":"344","author":"Goldberg","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0285","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.autrev.2022.103085_bb0290","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2022.103085_bb0295","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1158\/0008-5472.CAN-13-2690","article-title":"LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2022.103085_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086551","article-title":"Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation","volume":"9","author":"Sega","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2022.103085_bb0305","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.it.2003.10.001","article-title":"LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination","volume":"24","author":"Triebel","year":"2003","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0310","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1002\/1521-4141(2001010)31:10<2885::AID-IMMU2885>3.0.CO;2-2","article-title":"LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3\/TCR activation pathway","volume":"31","author":"Iouzalen","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0315","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","article-title":"Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients","volume":"108","author":"Gandhi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103085_bb0320","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2022.103085_bb0325","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nm.3179","article-title":"Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells","volume":"19","author":"Gagliani","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2022.103085_bb0330","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12929-017-0391-3","article-title":"Regulatory T cells induced by B cells: a novel subpopulation of regulatory T cells","volume":"24","author":"Chien","year":"2017","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.autrev.2022.103085_bb0335","first-page":"39","article-title":"Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications","volume":"380","author":"Roncarolo","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109080","article-title":"Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo","volume":"9","author":"Durham","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2022.103085_bb0345","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.4049\/jimmunol.172.9.5450","article-title":"Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo","volume":"172","author":"Workman","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0350","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4049\/jimmunol.174.2.688","article-title":"Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223)","volume":"174","author":"Workman","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0355","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.cell.2015.10.054","article-title":"SnapShot: T cell exhaustion","volume":"163","author":"Pauken","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2022.103085_bb0360","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00432-018-2620-x","article-title":"CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer","volume":"144","author":"Lee","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.autrev.2022.103085_bb0365","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.yexcr.2017.09.026","article-title":"Function and regulation of LAG3 on CD4(+)CD25(\u2212) T cells in non-small cell lung cancer","volume":"360","author":"Ma","year":"2017","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.autrev.2022.103085_bb0370","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2016.148965","article-title":"Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia","volume":"102","author":"Shapiro","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2022.103085_bb0375","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1158\/1078-0432.CCR-17-0950","article-title":"Characterization of the immune microenvironment in hepatocellular carcinoma","volume":"23","author":"Yarchoan","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.autrev.2022.103085_bb0380","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","article-title":"Role of cytokines in rheumatoid arthritis","volume":"14","author":"Feldmann","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0385","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00002281-200405000-00008","article-title":"T-cell regulation in rheumatoid arthritis","volume":"16","author":"Goronzy","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103085_bb0390","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cca.2016.02.010","article-title":"Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis","volume":"455","author":"Mateen","year":"2016","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2022.103085_bb0395","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13075-017-1309-x","article-title":"Interleukin-10-producing LAG3(+) regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis","volume":"19","author":"Nakachi","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2022.103085_bb0400","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.jid.2018.05.021","article-title":"Proportion of CD4(+)CD49b(+)LAG-3(+) type 1 regulatory T cells in the blood of psoriasis patients inversely correlates with psoriasis area and severity index","volume":"138","author":"Kim","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2022.103085_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107722","article-title":"Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis","volume":"96","author":"Yu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2022.103085_bb0410","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5114\/ada.2018.75609","article-title":"Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis","volume":"35","author":"Bartosinska","year":"2018","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.autrev.2022.103085_bb0415","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5385102","article-title":"Suppressed programmed death 1 expression on CD4(+) and CD8(+) T cells in psoriatic patients","volume":"2017","author":"Bartosinska","year":"2017","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.autrev.2022.103085_bb0420","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1210\/jc.2018-00498","article-title":"Patients with autoimmune thyroiditis show diminished levels and defective suppressive function of Tr1 regulatory lymphocytes","volume":"103","author":"Vitales-Noyola","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2022.103085_bb0425","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4049\/jimmunol.2100850","article-title":"Fewer LAG-3(+) T cells in relapsing-remitting multiple sclerosis and type 1 diabetes","volume":"208","author":"Jones","year":"2022","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0430","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.206.Supp.51.10","article-title":"T cells in relapsing-remitting multiple sclerosis demonstrate diminished expression of LAG-3","volume":"206","author":"Jones","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0435","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fimmu.2019.00835","article-title":"Blood levels of co-inhibitory-receptors: a biomarker of disease prognosis in multiple sclerosis","volume":"10","author":"Lavon","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0440","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3389\/fimmu.2019.01619","article-title":"CD4(+)CD25(+)LAG3(+) T cells with a feature of Th17 cells associated with systemic lupus erythematosus disease activity","volume":"10","author":"Kato","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0445","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41390-021-01588-2","article-title":"Juvenile idiopathic arthritis: lymphocyte activation gene-3 is a central immune receptor in children with oligoarticular subtypes","volume":"90","author":"Sag","year":"2021","journal-title":"Pediatr Res"},{"key":"10.1016\/j.autrev.2022.103085_bb0450","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus","volume":"67","author":"Postal","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0455","doi-asserted-by":"crossref","DOI":"10.1038\/s41590-022-01152-y","article-title":"Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells","author":"Sumida","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0460","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/rheumatology\/key069","article-title":"Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis","volume":"58","author":"Miyagawa","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103085_bb0465","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103085_bb0470","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103085_bb0475","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/rheumatology\/ker300","article-title":"A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm","volume":"51","author":"Tak","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103085_bb0480","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2217\/pgs.11.114","article-title":"Genetic and genomic predictors of anti-TNF response","volume":"12","author":"Prajapati","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.autrev.2022.103085_bb0485","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00011-005-1355-8","article-title":"Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines","volume":"54","author":"Herman","year":"2005","journal-title":"Inflamm Res"},{"key":"10.1016\/j.autrev.2022.103085_bb0490","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.39031","article-title":"Methotrexate restores regulatory T cell function through demethylation of the FoxP3 upstream enhancer in patients with rheumatoid arthritis","volume":"67","author":"Cribbs","year":"2015","journal-title":"Arthrit Rheumatol"},{"key":"10.1016\/j.autrev.2022.103085_bb0495","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10875-011-9542-6","article-title":"Combined treatment of etanercept and MTX reverses Th1\/Th2, Th17\/Treg imbalance in patients with rheumatoid arthritis","volume":"31","author":"Lina","year":"2011","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0500","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ced.13795","article-title":"Effect of methotrexate monotherapy on T-cell subsets in the peripheral circulation in psoriasis","volume":"44","author":"Priyadarssini","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2022.103085_bb0505","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nri802","article-title":"Development of anti-TNF therapy for rheumatoid arthritis","volume":"2","author":"Feldmann","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0510","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood-2005-11-4567","article-title":"TNF downmodulates the function of human CD4+CD25hi T-regulatory cells","volume":"108","author":"Valencia","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103085_bb0515","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/ard.61.4.311","article-title":"Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation","volume":"61","author":"den Broeder","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103085_bb0520","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1023\/A:1020543625282","article-title":"Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy","volume":"19","author":"Ohshima","year":"1999","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0525","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1592\/phco.30.4.339","article-title":"Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis","volume":"30","author":"Wiens","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.autrev.2022.103085_bb0530","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1196\/annals.1361.095","article-title":"Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab","volume":"1051","author":"Toubi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2022.103085_bb0535","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1084\/jem.20061531","article-title":"Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta","volume":"204","author":"Nadkarni","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2022.103085_bb0540","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.20040165","article-title":"Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy","volume":"200","author":"Ehrenstein","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2022.103085_bb0545","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1084\/jem.20151255","article-title":"Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis","volume":"213","author":"Nguyen","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2022.103085_bb0550","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jaci.2018.04.026","article-title":"Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis","volume":"142","author":"Nguyen","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0555","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103085_bb0560","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2022.103085_bb0565","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/j.gastro.2004.11.060","article-title":"Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha","volume":"128","author":"Mitoma","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2022.103085_bb0570","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.phrs.2016.11.025","article-title":"Transmembrane TNF-alpha reverse signaling leading to TGF-beta production is selectively activated by TNF targeting molecules: therapeutic implications","volume":"115","author":"Szondy","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.autrev.2022.103085_bb0575","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103085_bb0580","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103085_bb0585","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.1078231","article-title":"Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells","volume":"299","author":"Pasare","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.autrev.2022.103085_bb0590","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.4049\/jimmunol.179.4.2041","article-title":"Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells","volume":"179","author":"Dominitzki","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0595","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature07021","article-title":"IL-21 and TGF-beta are required for differentiation of human T(H)17 cells","volume":"454","author":"Yang","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2022.103085_bb0600","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ni1496","article-title":"Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells","volume":"8","author":"Acosta-Rodriguez","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0605","first-page":"77","article-title":"Targeting IL-6 signalling in early rheumatoid arthritis is followed by Th1 and Th17 suppression and Th2 expansion","volume":"32","author":"Guggino","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2022.103085_bb0610","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/cei.12017","article-title":"Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients","volume":"171","author":"Pesce","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0615","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.34477","article-title":"Brief report: inhibition of interleukin-6 function corrects Th17\/Treg cell imbalance in patients with rheumatoid arthritis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103085_bb0620","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12891-016-1137-1","article-title":"The balance between Foxp3 and Ror-gammat expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis","volume":"17","author":"Tada","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.autrev.2022.103085_bb0625","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/art.38246","article-title":"Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis","volume":"66","author":"Thiolat","year":"2014","journal-title":"Arthrit Rheumatol"},{"key":"10.1016\/j.autrev.2022.103085_bb0630","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13075-015-0526-4","article-title":"Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response","volume":"17","author":"Kikuchi","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2022.103085_bb0635","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1084\/jem.20141030","article-title":"Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity","volume":"212","author":"Paterson","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2022.103085_bb0640","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-065X.2009.00780.x","article-title":"The clinical utility of inhibiting CD28-mediated costimulation","volume":"229","author":"Linsley","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2022.103085_bb0645","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3899\/jrheum.091066","article-title":"Abatacept for rheumatoid arthritis: a Cochrane systematic review","volume":"37","author":"Maxwell","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2022.103085_bb0650","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s10875-011-9527-5","article-title":"CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis","volume":"31","author":"Alvarez-Quiroga","year":"2011","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0655","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/rheumatology\/kev403","article-title":"Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis","volume":"55","author":"Bonelli","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103085_bb0660","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.1038\/s41598-021-83615-0","article-title":"Abatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance","volume":"11","author":"Alenazy","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2022.103085_bb0665","doi-asserted-by":"crossref","first-page":"30639","DOI":"10.1073\/pnas.2007935117","article-title":"Aberrant expression of USF2 in refractory rheumatoid arthritis and its regulation of proinflammatory cytokines in Th17 cells","volume":"117","author":"Hu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2022.103085_bb0670","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/gm463","article-title":"Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease","volume":"5","author":"Mesko","year":"2013","journal-title":"Genome Med"},{"key":"10.1016\/j.autrev.2022.103085_bb0675","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2022.103085_bb0680","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/jid.2011.139","article-title":"Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin","volume":"131","author":"Bovenschen","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2022.103085_bb0685","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4049\/jimmunol.174.1.164","article-title":"Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation","volume":"174","author":"Sugiyama","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0690","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd3683","article-title":"Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer","volume":"12","author":"von Boehmer","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2022.103085_bb0695","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3109\/08916934.2012.682666","article-title":"Adoptive transfer of all-trans-retinal-induced regulatory T cells ameliorates experimental autoimmune arthritis in an interferon-gamma knockout model","volume":"45","author":"Jeon","year":"2012","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2022.103085_bb0700","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7573154","article-title":"Adoptive cell therapy of induced regulatory T cells expanded by tolerogenic dendritic cells on murine autoimmune arthritis","volume":"2017","author":"Yang","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2022.103085_bb0705","first-page":"427","article-title":"Depletion of regulatory T cells leads to an exacerbation of delayed-type hypersensitivity arthritis in C57BL\/6 mice that can be counteracted by IL-17 blockade","volume":"9","author":"Atkinson","year":"2016","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.autrev.2022.103085_bb0710","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/cei.12466","article-title":"Depletion of regulatory T cells in a hapten-induced inflammation model results in prolonged and increased inflammation driven by T cells","volume":"179","author":"Christensen","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0715","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaut.2016.02.002","article-title":"Lymphocyte-activation gene 3(+) (LAG3(+)) forkhead box protein 3(\u2212) (FOXP3(\u2212)) regulatory T cells induced by B cells alleviates joint inflammation in collagen-induced arthritis","volume":"68","author":"Chen","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103085_bb0720","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.autrev.2022.103085_bb0725","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4049\/jimmunol.1900823","article-title":"A LAG-3-specific agonist antibody for the treatment of T cell-induced autoimmune diseases","volume":"204","author":"Angin","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103085_bb0730","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092112","article-title":"LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia","volume":"13","author":"Sordo-Bahamonde","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.autrev.2022.103085_bb0735","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105282","article-title":"Understanding LAG-3 Signaling","volume":"22","author":"Chocarro","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2022.103085_bb0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102504","article-title":"LAG3 (CD223) and autoimmunity: emerging evidence","volume":"112","author":"Hu","year":"2020","journal-title":"J Autoimmun"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222000556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222000556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:25:38Z","timestamp":1761600338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997222000556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":148,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1568997222000556"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103085","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103085"}}